^
Association details:
| Biomarker: | ALK rearrangement |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1131P - Overall survival after treatment with first-line crizotinib or alectinib in patients with stage IV NSCLC and ALK rearrangement: A real-world nationwide cohort study from the Netherlands
Published date:
09/05/2022
Excerpt:
...we selected patients diagnosed between 2015 and 2019 with stage IV non-squamous NSCLC and an ALK rearrangement, treated in first line with crizotinib or alectinib....Three-year overall survival was 50% (95% CI 43-57) and outcome was considerably better for patients treated with alectinib (67%, 95% CI 55-76) than for crizotinib (37%, 95% CI 28-46).
